FIELD: biotechnology.
SUBSTANCE: invention relates to an immunogenic composition against H5 avian influenza virus containing the hemagglutinin protein of H5 avian influenza virus. Also the following is disclosed: a method of differentiating animals naturally infected with an avian influenza virus from animals vaccinated with the above immunogenic composition, comprising analyzing a sample of the animal in an immunoassay and/or genomic analytical assay for the presence of an avian influenza marker that is not present in the specified immunogenic composition, or analyzing the sample animal in an immunoassay and/or genomic assay for the presence of an avian influenza marker that is specific to said immunogenic composition.
EFFECT: invention is effective for the prevention and/or treatment of infections caused by avian influenza virus.
13 cl, 4 dwg, 10 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE TO SWINE INFLUENZA A VIRUS | 2018 |
|
RU2787596C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| RECOMBINANT VECTORS EXPRESSING AVIAN INFLUENZA VIRUS ANTIGENS AND APPLICATIONS THEREOF | 2017 |
|
RU2761869C2 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| VACCINE AGAINST FELINE LEUKEMIA VIRUS | 2018 |
|
RU2784533C2 |
| POLYVALENT VACCINE FOR CATS | 2018 |
|
RU2797538C2 |
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
| HEMAGLUTININ MUTANTS OF INFLUENZA VIRUS | 2019 |
|
RU2809237C2 |
| VACCINE AGAINST FELINE CALICIVIRUS | 2018 |
|
RU2792898C2 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
